Calidi Biotherapeutics, Inc. (CLDI)
USD 1.44
(-16.76%)
USD 1.44
(-16.76%)
| Breakdown | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|
| Revenue | - | 45 Thousand | 449 Thousand | - |
| Cost of Revenue | 1.25 Million | 274 Thousand | 94 Thousand | - |
| Gross Profit | -1.25 Million | -229 Thousand | 355 Thousand | - |
| Operating Expenses | 28.99 Million | 22.89 Million | 1.78 Million | 6.77 Million |
| Selling, General and Administrative Expenses | 15.98 Million | 15.64 Million | 1.78 Million | 3.59 Million |
| Research and Development Expenses | 13 Million | 7.25 Million | 4.67 Million | 3.18 Million |
| Other Expenses | - | -5000.00 | 9000.00 | 4000.00 |
| Cost and Expenses | 28.99 Million | 23.17 Million | 1.78 Million | 6.77 Million |
| Operating Income | -28.99 Million | -23.12 Million | -1.78 Million | -6.77 Million |
| Interest Expense | 1.06 Million | 158 Thousand | 614 Thousand | 163 Thousand |
| Income Tax Expense | 16 Thousand | 11 Thousand | 11 Thousand | 4000.00 |
| Earnings before Tax | -29.2 Million | -25.41 Million | 3.38 Million | -7.93 Million |
| Net Income | -29.21 Million | -25.42 Million | 3.38 Million | -7.93 Million |
| Earnings Per Share Basic | -1.73 | -29.90 | 1.18 | -0.22 |
| Earnings Per Share Diluted | -17.30 | -29.90 | 1.18 | -0.22 |
| Weighted Average Shares Outstanding | 16.88 Million | 850.5 Thousand | 2.87 Million | 35.9 Million |
| Weighted Average Shares Outstanding (Diluted) | 1.68 Million | 850.5 Thousand | 2.87 Million | 35.9 Million |
| Gross Margin | - | -5.09 | 0.79 | - |
| EBIT Margin | - | -508.18 | -3.97 | - |
| Profit Margin | - | -565.04 | 7.54 | - |
| EBITDA | -28.6 Million | -24.99 Million | -9.45 Million | -6.65 Million |
| Earnings Before Tax Margin | - | -513.96 | -3.97 | - |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 FY | 2023 Q4 | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - |
| Cost of Revenue | 378 Thousand | 374 Thousand | 1.25 Million | 364 Thousand | 100 Thousand | - |
| Gross Profit | -378 Thousand | -374 Thousand | -1.25 Million | -364 Thousand | -100 Thousand | - |
| Operating Expenses | 5.39 Million | 6.37 Million | 27.73 Million | 9.45 Million | 7.12 Million | 1.49 Million |
| Selling, General and Administrative Expenses | 3.22 Million | 3.63 Million | - | 5.49 Million | 3.87 Million | 1.49 Million |
| Research and Development Expenses | 2.16 Million | 2.74 Million | - | 3.95 Million | 3.25 Million | 3.17 Million |
| Other Expenses | 10 Thousand | -17 Thousand | -51 Thousand | -22 Thousand | -8000.00 | -16 Thousand |
| Cost and Expenses | 5.77 Million | 6.75 Million | 28.99 Million | 9.82 Million | 7.22 Million | 1.49 Million |
| Operating Income | -5.77 Million | -6.75 Million | -28.99 Million | -9.82 Million | -7.22 Million | -1.49 Million |
| Interest Expense | 273 Thousand | 253 Thousand | 1.06 Million | 222 Thousand | 324 Thousand | 306 Thousand |
| Income Tax Expense | 8000.00 | 4000.00 | 16 Thousand | -3000.00 | 11 Thousand | 77.94 Thousand |
| Earnings before Tax | -5.75 Million | -7.22 Million | -29.2 Million | -8.23 Million | -2.01 Million | -4.19 Million |
| Net Income | -5.76 Million | -7.22 Million | -29.21 Million | -3.55 Million | -2.02 Million | -4.26 Million |
| Earnings Per Share Basic | -1.08 | -2.03 | - | -1.00 | -1.41 | -4.32 |
| Earnings Per Share Diluted | -1.08 | -2.03 | - | -1.00 | -1.41 | -4.32 |
| Weighted Average Shares Outstanding | 5.32 Million | 3.55 Million | 1.68 Million | 3.55 Million | 1.43 Million | 987.8 Thousand |
| Weighted Average Shares Outstanding (Diluted) | 5.32 Million | 3.55 Million | 1.68 Million | 3.55 Million | 1.43 Million | 987.8 Thousand |
| Gross Margin | - | - | - | - | - | - |
| EBIT Margin | - | - | - | - | - | - |
| Profit Margin | - | - | - | - | - | - |
| EBITDA | -5.39 Million | -6.37 Million | - | -9.45 Million | -7.12 Million | -1.49 Million |
| Earnings Before Tax Margin | - | - | - | - | - | - |
APPF
0TIQ
HSTA
RRDMF
TOUP
6936